45 completed, 27 unknown, 9 terminated, 4 withdrawn. 91 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 91 | Completed 45, Unknown 27, Terminated 9, Withdrawn 4, Not yet recruiting 3, Active not recruiting 2, Recruiting 1 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA Romiplostim - Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2024-08-02 | 2024-08-02 |
| Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA rhTPO, Cyclosporin A - Aplastic Anemia, Transfusion-dependent Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 54 | 2024-07-30 | 2024-07-29 |
| Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study Romiplostim - Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2024-07-30 | 2024-07-24 |
| A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag Lusutrombopag - Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2024-06-01 | 2024-05-23 |
| Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA Luspatercept, cyclosporine - Aplastic Anemia | Phase 4 | Withdrawn | Peking Union Medical College Hospital | 2024-05-01 | 2026-06-04 | |
| The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA Busulfan, Flu/Cy/ATG or Cy/ATG - Severe Aplastic Anemia | Phase 4 | Unknown | Peking University People's Hospital | 160 | 2023-11-15 | 2023-11-18 |
| CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit - Aplastic Anemia | Phase 4 | Completed | Peking Union Medical College Hospital | 86 | 2023-09-15 | 2025-04-30 |
| A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA Herombopag + CsA, rhTPO combined with Herombopag + CsA - Aplastic Anemia, Drug Effect | Phase 4 | Unknown | Peking Union Medical College Hospital | 90 | 2023-08-01 | 2023-08-22 |
| Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS Roxadustat, Luspatercept - Myelodysplastic Syndromes | Phase 4 | Unknown | Peking Union Medical College Hospital | 62 | 2023-08-01 | 2023-08-23 |
| Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS Lenalidomide, Azacitidine - Myelodysplastic Syndromes | Phase 4 | Unknown | Peking Union Medical College Hospital | 138 | 2023-08-01 | 2023-08-22 |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors Hydroxyurea - Polycythemia Vera | Phase 4 | Terminated | Novartis Pharmaceuticals | 76 | 2023-07-28 | 2026-08-18 |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India Luspatercept - Anemia | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 85 | 2023-06-05 | 2026-08-31 |
| Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System CsA+ATG+Herombopag, CsA+Herombopag - Aplastic Anemia, CSA | Phase 4 | Unknown | Peking Union Medical College Hospital | 210 | 2023-01-20 | 2023-08-24 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-11-09 |
| A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis Ruxolitinib - Myelofibrosis | Phase 4 | Unknown | Qilu Hospital of Shandong University | 87 | 2022-06-10 | 2022-07-07 |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Flumatinib, Imatinib - CML, Chronic Phase | Phase 4 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2400 | 2022-04-30 | 2022-05-10 |
Showing 20 of 91. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Myelodysplastic Syndromes (26) · Anemia, Aplastic (19) · Leukemia, Myeloid, Chronic-Phase (8) · Leukemia, Myeloid, Acute (7) · Iron Overload (5) · Leukemia (5) · Myeloproliferative Disorders (4) · Primary Myelofibrosis (4) · Blast Crisis (3) · Bronchiolitis Obliterans Syndrome (3) · Hematologic Diseases (3) · Hemoglobinuria, Paroxysmal (3) · Polycythemia Vera (3)
Hemic and Lymphatic Diseases (91) · Hematologic Diseases (88) · Neoplasms (46) · Neoplasms by Histologic Type (45) · Leukemia, Myeloid (43) · Myeloproliferative Disorders (41) · Pathological Conditions, Signs and Symptoms (41) · Leukemia (40) · Pathologic Processes (38) · Disease Attributes (37) · Chronic Disease (36) · Anemia (28) · Bone Marrow Failure Disorders (20) · Immune System Diseases (8)
nilotinib (14) · Imatinib Mesylate (11) · Cyclosporine (8) · Deferasirox (8) · Antilymphocyte Serum (5) · Dasatinib (5) · Cyclophosphamide (4) · luspatercept (4) · ruxolitinib (4) · Azacitidine (3) · Busulfan (3) · Decitabine (3) · Chelating Agents (2) · Hydroxyurea (2) · asciminib (2)
Novartis Pharmaceuticals (25) · Peking Union Medical College Hospital (11) · PETHEMA Foundation (3) · Alexion Pharmaceuticals, Inc. (2) · Bristol-Myers Squibb (2) · Chinese Academy of Medical Sciences (2) · Cttq (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Shenzhen Second People's Hospital (2) · Association pour la recherche sur les Affections Malignes en Immunologie Sanguine (1) · Celgene (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese Society of Hematology (1) · Dong-A ST Co., Ltd. (1) · Dong-Wook Kim (1)
China (29) · United States (16) · France (10) · Germany (9) · Spain (9) · Italy (8) · South Korea (8) · Canada (7) · United Kingdom (6) · Poland (5) · Russia (5) · Hungary (4) · India (4) · Israel (4) · Netherlands (4)
Bing Bing, PhD (3) · Bing Han, PhD (2) · Jun Ma (2) · Sanz Guillermo, Dr (2) · Alessandra Iurlo, MD (1) · Alexander Coltoff, MD (1) · Alexander Ngwube, MD (1) · Andreas Hochhaus, Professor, MD (1) · Arnon Nagler, MD (1) · Barry R. Meisenberg, MD (1) · Bruno Martino, MD (1) · C L Beach, PharmD (1)
PMID 1090310, PMID 19720924, PMID 20220063, PMID 20421274, PMID 21663651, PMID 21670449, PMID 22198540, PMID 23073603, PMID 24838091, PMID 25170123, PMID 25932194, PMID 26622526, PMID 26876245, PMID 26993758, PMID 27537786, PMID 27771544, PMID 29577674, PMID 30368038, PMID 30912699, PMID 32572189, PMID 33123978, PMID 33305842, PMID 33639900, PMID 33875811, PMID 35235189, PMID 35911824, PMID 38007586, PMID 38484432, PMID 39164407, PMID 41114449
2004 (1), 2009 (1), 2014 (1), 2015 (1), 2019 (1), 2023 (1)